• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Prevalence and Incidence of Demodex Blepharitis

Video

Douglas K Devries, OD, illustrates the current prevalence of patients diagnosed with Demodex blepharitis.

Douglas K. Devries, OD: I’ve been aware of the prevalence of Demodex blepharitis for years. As I studied patients with dry eye and I was looking for underlying causes, I began to look at some of the research, and I was astounded by some of the early research. One particular paper out of the UK said that as somebody got into their sixth or seventh decade, [prevalance] could be as high as 85% or 90%. I started looking for Demodex blepharitis on a regular basis, and I found this tremendous prevalence. There are certain factors that we look at, which we’ll discuss as well.

When we examine the pathophysiology of Demodex blepharitis, it’s a mite. It’s a parasite. We tend to find a prevalence in patients with ocular rosacea. Patients with ocular or facial rosacea tend to be lighter-skinned, such as a Fitzpatrick type 1, type 2, or perhaps type 3. A lot of times, we find that it tends to be much more prevalent in individuals who are of Irish, English, or Scottish descent. How it presents when a patient becomes symptomatic is that these little mites in the eyelashes begin to proliferate. In some individuals, they proliferate because it’s the right physiologic environment to do so. Typically, a mite needs a food source. When we have a food source, such as polysaccharides from biofilm, they tend to start growing in numbers.

Many individuals have Demodex—not necessarily the blepharitis—but they aren’t symptomatic. But when the right physiologic environment gets set up—in other words, the polysaccharides—we see them increase in numbers. It’s very interesting with patients. They’ll want to scratch their eyelash margin. It isn’t an itch like you’d find in an allergic reaction. They’re very specific with where they’re bothered. The reason that they’re bothered and wanting to scratch the eyelash margin is because as those Demodex blepharitis proliferate, they release exotoxins. The exotoxins then have this whole reaction with the body in which the individual becomes inflamed and the eyelid margins become inflamed and thicken, so they want to scratch that. The pathophysiology dictates that it’s going to create additional inflammation on those patients. In those patients with dry eye, that’s 1 more source of inflammation that’s going to cause the patient discomfort.

Transcript edited for clarity.

Related Videos
Video 9 - "Denial of Coverage in Fertility Care"
Video 8 - "Risks of Miscarriage and Multiple Births Associated with Fertility Care"
Video 7 - "Fertility Preservation: Egg Freezing Versus Embryo Freezing"
Video 6 - "Family Building Costs, Barriers, and Dropout Rates Associated with Fertility Care"
Video 5 - "Closing Payer Gaps and Improving Fertility Care Access"
Video 4 - "Increasing Employer Coverage and Maximizing Fertility Benefits "
Video 5 - "Relevance of NUTURE Study Findings for Patients, Payers, Providers"
Video 3 - "Improving IVF Success Rates & Utilizing AI in Fertility Health Care"
Video 2 - "Holistic Fertility Management and Payer Collaboration"
Video 5 - "Relevance of NUTURE Study Findings for Patients, Payers, Providers"
Related Content
© 2024 MJH Life Sciences

All rights reserved.